Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pilot Study of Nivolumab and Procaspase Activating Compound-1 (PAC-1) for

NCT03927248 is registered in ClinicalTrials.gov with HealthPartners Institute as lead sponsor.

NCT NCT03927248
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03927248 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pilot Study of Nivolumab and Procaspase Activating Compound-1 (PAC-1) for
Lead sponsor
HealthPartners Institute
Phase
Phase 1/2
Overall status
Withdrawn
Start date
September 30, 2020
Completion date
December 31, 2021
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic renal cell carcinoma